Development and characterization of polymer lipid hybrid nanoparticles for oral delivery of LMWH

References

• Agarwal V, Khan MA. 2001. Current status of the oral delivery of insulin. Pharm Technol. 10:76–90.
   Google Scholar
• Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, et al. 2007. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 50:e1–e157.
   PubMed Web of Science ®Google Scholar
• Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. 2004. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol. 44:E1–E211.
   PubMedGoogle Scholar
• Bagre AP, Jain K, Jain NK. 2013. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment. Int J Pharm. 456:31–40.
   PubMed Web of Science ®Google Scholar
• Bai S, Ahsan F. 2009. Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. Pharm Res. 26:539–548.
   PubMed Web of Science ®Google Scholar
• Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV. 2001. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med. 344:626–631.
   PubMed Web of Science ®Google Scholar
• Calvo P, Remunan‐Lopez C, Vila‐Jato J, Alonso M. 1997. Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci. 63:125–132.
   Web of Science ®Google Scholar
• Chen MC, Wong HS, Lin KJ, Chen HL, Wey SP, Sonaje K, et al. 2009. The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin. Biomaterials. 30:6629–6637.
   PubMed Web of Science ®Google Scholar
• Cheow WS, Hadinoto K. 2011. Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles. Colloids Surf B Biointerfaces. 85:214–220.
   PubMed Web of Science ®Google Scholar
• Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. 2008. Prevention of venous thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST J. 133:381S–453S.
   PubMed Web of Science ®Google Scholar
• Hallan SS, Kaur P, Kaur V, Mishra N, Vaidya B. 2016. Lipid polymer hybrid as emerging tool in nanocarriers for oral drug delivery. Artif Cells Nanomed Biotechnol. 44:334–349.
   PubMed Web of Science ®Google Scholar
• Hayes PY, Ross BP, Thomas BG, Toth I. 2006. Polycationic lipophilic-core dendrons as penetration enhancers for the oral administration of low molecular weight heparin. Bioorg Med Chem. 14:143–152.
   PubMed Web of Science ®Google Scholar
• Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C, Ubrich N. 2006. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J Control Release. 113:38–42.
   PubMed Web of Science ®Google Scholar
• Hull RD, Pineo GF, Raskob GE. 2004. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Pathophysiol Haemost Thromb. 28(Suppl. 3):8–16.
   Google Scholar
• Hwang SR, Seo DH, Al-Hilal TA, Jeon OC, Kang JH, Kim SH, et al. 2012. Orally active desulfated low molecular weight heparin and deoxycholic acid conjugate, 6ODS-LHbD, suppresses neovascularization and bone destruction in arthritis. J Control Release. 163:374–384.
   PubMed Web of Science ®Google Scholar
• Javot L, Lecompte T, Rabiskova M, Maincent P. 2009. Encapsulation of low molecular weight heparins: influence on the anti-Xa/anti-IIa ratio. J Control Release. 139:8–14.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Ubrich N, Marchand-Arvier M, Vigneron C, Hoffman M, Lecompte T, et al. 2002. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation. 105:230–235.
   PubMed Web of Science ®Google Scholar
• Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. 2008. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians evidence-based clinical practice guidelines. CHEST J. 133:454S–545S.
   PubMed Web of Science ®Google Scholar
• Kim CY, Kim J, Han K, Kim S, Park K, Byun Y. 2007a. Toxicity screening after repeated dose of a newly developed oral heparin derivative in male cynomolgus monkeys. J Toxicol Sci. 32:411–420.
   PubMedGoogle Scholar
• Kim SK, Huh J, Kim SY, Byun Y, Lee DY, Moon HT. 2011. Physicochemical conjugation with deoxycholic acid and dimethylsulfoxide for heparin oral delivery. Bioconjug Chem. 22:1451–1458.
   PubMed Web of Science ®Google Scholar
• Kim SK, Lee DY, Kim CY, Nam JH, Moon HT, Byun Y. 2007b. A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study. J Control Release. 123:155–163.
   PubMed Web of Science ®Google Scholar
• Lensing AW, Prandoni P, Prins MH, Büller H. 1999. Deep-vein thrombosis. The Lancet. 353:479–485.
   PubMed Web of Science ®Google Scholar
• Liautard C, Nunes A-MC, Vial T, Chatillon F, Guy C, Ollagnier M, et al. 2002. Low-molecular-weight heparins and thrombocytosis. Ann Pharmacother. 36:1351–1354.
   PubMed Web of Science ®Google Scholar
• Markovich RJ, Pidgeon C. 2007. Introduction to Fourier transform infrared spectroscopy and applications in the pharmaceutical sciences. Pharm Res. 8:663–675.
   Web of Science ®Google Scholar
• Mukherjee S, Ray S, Thakur R. 2007. The current status of solid lipid nanoparticles. Pharmabit XV. 1:53–60.
   Google Scholar
• Paliwal R, Paliwal SR, Agrawal GP, Vyas SP. 2011. Biomimetic solid lipid nanoparticles for oral bioavailability enhancement of low molecular weight heparin and its lipid conjugates: in vitro and in vivo evaluation. Mol Pharm. 8:1314–1321.
   PubMed Web of Science ®Google Scholar
• Paliwal R, Paliwal SR, Agrawal GP, Vyas SP. 2012. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: in vitro and in vivo evaluation. Int J Pharm. 422:179–184.
   PubMed Web of Science ®Google Scholar
• Paliwal R, Rai S, Vaidya B, Khatri K, Goyal AK, Mishra N, et al. 2009. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomed: Nanotechnol Biol Med. 5:184–191.
   PubMed Web of Science ®Google Scholar
• Ramadan A, Lagarce F, Tessier-Marteau A, Thomas O, Legras P, Macchi L, et al. 2011. Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study. Int J Nanomed. 6:2941.
   PubMed Web of Science ®Google Scholar
• Rawat A, Majumder QH, Ahsan F. 2008. Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation. J Control Release. 128:224–232.
   PubMed Web of Science ®Google Scholar
• Rejman J, Oberle V, Zuhorn I, Hoekstra D. 2004. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J. 377:159–169.
   PubMed Web of Science ®Google Scholar
• Vyas S, Rai S, Paliwal R, Gupta PN, Khatri K, Goyal AK, et al. 2008. Solid lipid nanoparticles (SLNs) as a rising tool in drug delivery science: one step up in nanotechnology. Curr Nanosci. 4:30–44.
   Web of Science ®Google Scholar
• Yang T, Nyiawung D, Silber A, Hao J, Lai L, Bai S. 2012. Comparative studies on chitosan and polylactic-co-glycolic acid incorporated nanoparticles of low molecular weight heparin. AAPS PharmSciTech. 13:1309–1318.
   PubMed Web of Science ®Google Scholar